



03.25.02

RECEIVED
MAR 28 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 01-033)

In the Application of:

Sarah S. Bacus

Serial No.: 09/760,120

Filing Date: January 12, 2001

For: Method for Quantitating a Protein
By Image Analysis

Examiner:

Group Art Unit: 1641

TRANSMITTAL LETTER

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In regard to the above identified application,

1. We are transmitting herewith the attached:

- a) Information Disclosure Statement;
- b) PTO Form 1449; and cited references
- c) Return postcard

2. With respect to fees:

- a) No fees are required
- b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.

3. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1, are being deposited with the United States Postal Service with sufficient postage Express Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231 on March 20, 2002.

Respectfully submitted,

Date: 20 March 2002

Kevin E. Noonan
Registration No. 35,303



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 01-033)

#4
RECEIVED
MAR 28 2002
TECH CENTER 1600/2900

In the Application of:

Sarah S. Bacus

Serial No.: 09/760,120

Filing Date: January 12, 2001

For: Method for Quantitating a Protein
By Image Analysis

)
)
) Examiner:
)
) Group Art Unit: 1641
)
)
)
)
)
)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the references cited below are enclosed. These references are also listed on the enclosed PTO Form 1449.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief be in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned representative by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

U.S. Patent Documents

6,165,734	Buckwald et al.	December 26, 2000
5,998,151	Fisher et al.	December 7, 1999

5,514,554 Bacus Sarah April 13, 1993

5,202,931 Bacus James April 13, 1993

Foreign Patent Documents

WO 00/23799 A Smith, Steven April 27, 2000

EP 0378 383 Univ. Arizona July 18, 1990

WO 93 03741 Yeda Res. & Dev. March 4, 1993

Other Documents

Van Diest et al., Analytical Cellular Pathology, vol. 3, no. 4, 1991, pages 195-202.

Bacus et al., Archives of Pathology and Laboratory Medicine, vol. 114, no. 2, 1990, pages 164-169

Bacus et al., American Journal of Pathology, vol. 137, no.1, July 1990, pages 103-111

Muss et al., 1994, N. Engl. J. Med. 330:1260-66

Kraus et al., 1989, Proc. Natl. Acad. Sci. U.S.A. 86:9193-97

Mendelsohn, 1990, Semin. Cancer Biol. 1:339-44

Hancock et al., 1991, Cancer Res. 51:4575-80

Peles et al., 1991, EMBO J. 10:2077-86

Peles et al., 1992, Cell 69:205-16

Arteaga et al., 1994, Cancer Res., 54:3758-65

Pietras et al., 1994, Oncogene 9:1829-38

Cobleigh et al., 1999, J. Clin. Oncol. 17:2639-48

DiGiovanna, 1999, PPO Updates: Princ. Practice Oncol. 13:1-9

Shak, 1999, Semin. Oncol. 26:71-77

Sliwkowski et al., 1999, Semin. Oncol. 26:60-70

Vincent et al., 2000, Cancer Chemother. Pharmacol. 45:231-38

Lowry et al., 1951, J. Biol. Chem. 193:265-275

Date: March 20, 2002

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff

Kevin E. Noonan
Reg. No. 35,303